UA94579C2 - Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission - Google Patents

Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission

Info

Publication number
UA94579C2
UA94579C2 UAA200710593A UAA200710593A UA94579C2 UA 94579 C2 UA94579 C2 UA 94579C2 UA A200710593 A UAA200710593 A UA A200710593A UA A200710593 A UAA200710593 A UA A200710593A UA 94579 C2 UA94579 C2 UA 94579C2
Authority
UA
Ukraine
Prior art keywords
dithiolethiones
dysfunction
treatment
conditions associated
compounds
Prior art date
Application number
UAA200710593A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Бенджамин Друкарч
Антон Н.М. Шоффельмеер
Рулоф В. Фенстра
Мари-одиль Кристен
Жан-луиз Бюрго
Марилен Шолле
Баккер Воутер И. Ивема
Флит Бернард Ж. ван
Мартинус Т.М. Тульп
Original Assignee
Эббот Хелскеа Продактс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббот Хелскеа Продактс Б.В. filed Critical Эббот Хелскеа Продактс Б.В.
Publication of UA94579C2 publication Critical patent/UA94579C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

, (1)The invention relates to dithiolethiones derivatives as monoamino oxidase inhibitors, in particular MAO-B in-hibitors, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said dithiolethiones derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment, amelioration or prevention of conditions associated with dysfunction of monoamine neurotransmission. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.
UAA200710593A 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission UA94579C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101405 2005-02-24

Publications (1)

Publication Number Publication Date
UA94579C2 true UA94579C2 (en) 2011-05-25

Family

ID=34938805

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200710593A UA94579C2 (en) 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission

Country Status (14)

Country Link
EP (1) EP1858875A2 (en)
JP (1) JP2008531519A (en)
KR (1) KR20070117607A (en)
CN (1) CN101107240B (en)
AR (1) AR055862A1 (en)
AU (1) AU2006218012A1 (en)
BR (1) BRPI0609043A2 (en)
CA (1) CA2594165A1 (en)
MX (1) MX2007010380A (en)
RU (1) RU2402543C2 (en)
SA (1) SA06270023B1 (en)
TW (1) TW200640898A (en)
UA (1) UA94579C2 (en)
WO (1) WO2006089861A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
CN102807557B (en) * 2012-08-21 2015-02-04 苏州大学 3H-1,2-dithio-cyclopentene-3-thioketone compound and application thereof
KR101438415B1 (en) * 2013-07-25 2014-09-17 동국대학교 경주캠퍼스 산학협력단 Extract of Uncaria rhynchophylla for preventing or ameliorating the memory impairment
CN104788440B (en) * 2015-04-03 2017-12-26 苏州大学 Nicotinic acid derivates and its application
BR112019018495A2 (en) 2017-03-07 2020-04-14 Centre Hospitalier Univ Bordeaux derivatives of desmethylanetola trithion for the treatment of diseases related to the mitochondrial production of reactive oxygen species (ero)
FR3063640B1 (en) * 2017-03-07 2020-10-09 Elodie Petitjean TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN
JP7514841B2 (en) * 2018-09-18 2024-07-11 エスティー アイピー ホールディング エージー Rotational isomers of 4-alkyl-5-heteroaryl-3H-1,2-dithiole-3-thiones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1442450A (en) * 1964-05-05 1966-06-17 Monsanto Chemicals New heterocyclic compounds containing sulfur
JPH089611B2 (en) * 1988-06-20 1996-01-31 三井東圧化学株式会社 Novel 1,2-dithiole-3-thione derivative and immunomodulator containing the same as active ingredient
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
AU6462500A (en) * 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement

Also Published As

Publication number Publication date
TW200640898A (en) 2006-12-01
RU2402543C2 (en) 2010-10-27
SA06270023A (en) 2005-12-03
EP1858875A2 (en) 2007-11-28
RU2007135184A (en) 2009-03-27
CN101107240A (en) 2008-01-16
CN101107240B (en) 2011-02-09
WO2006089861A2 (en) 2006-08-31
MX2007010380A (en) 2007-09-25
SA06270023B1 (en) 2010-10-12
CA2594165A1 (en) 2006-08-31
KR20070117607A (en) 2007-12-12
AU2006218012A1 (en) 2006-08-31
JP2008531519A (en) 2008-08-14
BRPI0609043A2 (en) 2010-11-16
AR055862A1 (en) 2007-09-12
WO2006089861A3 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
WO2010005958A3 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
MX2010002258A (en) Therapeutic isoxazole compounds.
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
UA94579C2 (en) Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
SG165315A1 (en) Alpha2c adrenoreceptor agonists
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
WO2007011820A3 (en) Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EA201001585A1 (en) DERIVATIVES OF THYENOPYRIDONE AS AMP-ACTIVATED PROTEINKINASE (AMRC) ACTIVATORS
WO2008036653A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2006048330A8 (en) 11βετα-hsd1 inhibitors
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
MX2009000657A (en) Compositions and methods for the treatment of mucositis.
WO2007056159A3 (en) Hydrazone derivatives and uses thereof
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
MX2009007713A (en) Pyridazine derivatives, processes for their preparation and their use as fungicides.
HRP20080493T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
MX2010005649A (en) Novel compounds as cannabinoid receptor ligands and uses thereof.
ATE519373T1 (en) TEA COMPOSITION AND PROCESS FOR PRODUCTION THEREOF
WO2007126900A3 (en) Antifungal agents
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
WO2007017728A3 (en) Novel heterocyclic compounds
WO2005005389A3 (en) Malonamide derivatives